Real-world use of inhaled corticosteroid/formoterol as needed in adults with mild asthma: the PRIME study.

Inhaled corticosteroid/formoterol fumarate (ICS/FF) as needed is recommended by the Global Initiative for Asthma (GINA) as sole therapy in adults with mild asthma, with low-dose maintenance ICS plus short-acting β Adults with asthma receiving low-dose maintenance ICS, or as needed ICS/FF or SABA were followed for 6 months. Data collected included Asthma Control Test (ACT), Asthma Control Questionnaire 5-item (ACQ-5), forced expiratory volume in 1 s (FEV The study was conducted in 883 patients in Germany, Italy, Poland and Spain; 833 (94.3%) completed follow-up. At enrolment, 32.2% received maintenance ICS, 56.3% ICS/FF as needed and 11.6% SABA as needed; 57.4%, 61.2% and 54.9%, respectively, had well-controlled asthma (ACQ-5/ACT definition). After 6 months, changes in mean FEV More patients received ICS/FF as needed than SABA as needed, suggesting that physicians are aware of the latest treatment recommendations. This real-world study provides additional support to the use of ICS/FF as needed as preferred treatment for patients with mild asthma, whereas SABA as needed was associated with a fall in lung function and more severe exacerbations.

Informations de copyright

Copyright ©The authors 2024.

Déclaration de conflit d'intérêts

Conflicts of interest: In addition to the medical writing support disclosed above, the authors have the following conflicts of interest. G. Brusselle declares honoraria for advisory boards and/or lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis and Sanofi Regeneron, and that he is President of the Belgian Respiratory Society. All are outside the scope of the current manuscript. F. Blasi declares grants or contracts from AstraZeneca, Chiesi, GlaxoSmithKline and Insmed; consulting fees from GlaxoSmithKline, OM Pharma and Menarini; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Chiesi, GlaxoSmithKline, Grifols, Insmed, Menarini, Viatris, OM Pharma, Pfizer, Sanofi, Vertex and Zambon. All are outside the scope of the current manuscript. C. Gessner declares consulting fees and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GlaxoSmithKline, AstraZeneca, Chiesi, Pfizer, Sanofi, Berlin-Chemie, MSD, BMS, Boehringer Ingelheim, Teva, Roche, Regeneron and Novartis; support for attending meetings and/or travel from Chiesi and Sanofi; participation in a steering committee for the Regeneron lung cancer programme; and that he is chairman of the professional association of pneumologists in Saxony. All are outside the scope of the current manuscript. P. Kuna declares honoraria for lectures from Adamed, Boehringer Ingelheim, AstraZeneca, Celon Pharma, Polpharma, Berlin-Chemie Menarini, Glenmark, GlaxoSmithKline, Teva, Novartis and Sanofi; and support to attend congresses from AstraZeneca and Berlin-Chemie Menarini. All are outside the scope of the current manuscript. P. Wark has no conflicts to disclose. G. Cappellini, E. Oosterom, M. Van Der Deijl, E. Bucchioni and E. Topole are all employees of Chiesi, the study sponsor.